Positive new data suggests that more people facing advanced breast cancer may be able to put off treatment with harsh ...

A combination of Enhertu and Perjeta nearly doubled progression-free survival compared to standard therapy in data presented ...

HER2+ breast cancer usually undergo preoperative therapy with multi-agent chemotherapy in combination with anti-HER2 ...

The DESTINY-Breast09 study, reported at ASCO, compared antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) and ...

Study results unveiled at ASCO show combining Enhertu with Perjeta can significantly delay tumor growth versus a regimen that ...

AstraZeneca and Daiichi Sankyo’s drug extended survival by 30% compared to a widely used regimen, further establishing its ...

Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free ...

HER2+ breast cancer usually undergo pre-operative therapy with multi-agent chemotherapy in combination with anti-HER2 antibodies, followed by surgery.

CHICAGO -- Patients with progressive HER2-positive gastroesophageal (GE) cancer lived significantly longer when they received ...

to Herceptin ® (trastuzumab) and chemotherapy – – 21% reduction in the risk of death was seen in the pre-specified subgroup of people with lymph node-positive disease – – Data to be ...

Researchers at ASCO's annual meeting also discussed the importance of repeat biopsies to assess HER2 status after first-line treatment.

Ten-Year APHINITY Data Show Genentech’s Perjeta-based Regimen Reduced the Risk of Death by 17% in HER2-Positive Early-Stage Breast Cancer – Long term follow-up in this curative setting ...